Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lin has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Caiyun Jiang
Department of Colorectal Surgery, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of China
1 shared publicationChengwei Ye
Department of Colorectal Surgery, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of China
1 shared publication- Jie Pan
Department of Emergency Surgery, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of China
1 shared publication - Meifang Xu
Department of Pathology, Fujian Medical University Union Hospital, Fuzhou, China
1 shared publication - Mengxin Lin
Department of Pathology, Fujian Medical University Union Hospital, Fuzhou, Fujian, P.R. China
1 shared publication - Pan Chi
Department of Colorectal Surgery, Fujian Medical University Union Hospital, Fuzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 December 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 11255-11269
Demethylation and Overexpression of CSF2 are Involved in Immune Response, Chemotherapy Resistance, and Poor Prognosis in Colorectal Cancer
Purpose: This study aimed to evaluate the role of colony-stimulating factor 2 (CSF2) in chemotherapy resistance, prognosis, and immune response and to identify its possible mechanisms underlying drug resistance. Methods: Drug-resistant cell lines were obtained by successively increasing drug concentration. RNA-Seq was performed to screen hub genes. CSF2 expression was analyzed via immunohistochemistry. Moreover, The Cancer Genome Atlas (TCGA), Tumor Immune Estimation Resource (TIMER) dataset, and R2 platform were used to explore the correlations among CSF2 expression, prognosis, and immune response. Results: RNA-Seq indicated that microRNAs in cancer, P53 signaling pathway, and cell cycle were associated with FOLFOX chemotherapy resistance. Protein-protein interaction (PPI), molecular complex detection (MOCDE), and qRT-PCR analysis verified CSF2 as the hub gene in chemotherapy resistance. Moreover, CSF2 expression was lower in the normal tissue than in the cancerous tissue (PConclusion: CSF2 is a novel biomarker and a prognostic factor for the survival of CRC patients affecting the immune response, and an overexpression of CSF2 in CRC patients may be caused by DNA demethylation.
- 1 December 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 11255-11269
Open AccessDemethylation and Overexpression of CSF2 are Involved in Immune Response, Chemotherapy Resistance, and Poor Prognosis in Colorectal Cancer
Purpose: This study aimed to evaluate the role of colony-stimulating factor 2 (CSF2) in chemotherapy resistance, prognosis, and immune response and to identify its possible mechanisms underlying drug resistance. Methods: Drug-resistant cell lines were obtained by successively increasing drug concentration. RNA-Seq was performed to screen hub genes. CSF2 expression was analyzed via immunohistochemistry. Moreover, The Cancer Genome Atlas (TCGA), Tumor Immune Estimation Resource (TIMER) dataset, and R2 platform were used to explore the correlations among CSF2 expression, prognosis, and immune response. Results: RNA-Seq indicated that microRNAs in cancer, P53 signaling pathway, and cell cycle were associated with FOLFOX chemotherapy resistance. Protein-protein interaction (PPI), molecular complex detection (MOCDE), and qRT-PCR analysis verified CSF2 as the hub gene in chemotherapy resistance. Moreover, CSF2 expression was lower in the normal tissue than in the cancerous tissue (PConclusion: CSF2 is a novel biomarker and a prognostic factor for the survival of CRC patients affecting the immune response, and an overexpression of CSF2 in CRC patients may be caused by DNA demethylation.